A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NAT / nucleic acid amplification technology

[Related PubMed/MEDLINE]
Total Number of Papers: 230
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NAT  (>> Co-occurring Abbreviation)
Long Form:   nucleic acid amplification technology
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Comparing the Cobas Liat Influenza A/B and respiratory syncytial virus assay with multiplex nucleic acid testing. CARVs, LIAT, RSV, TAT
2019 Hepatitis E virus blood donor NAT screening: as much as possible or as much as needed? HEV, MP-NAT, TT-HEV
2019 Prevention of transfusion transmitted infections. PRT, TTI
2018 Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider. HCVAb, KDRI
2018 Impact of hepatitis E virus testing on the safety of blood components in Germany - results of a simulation study. HEV
2018 Rapid and sensitive detection of viral nucleic acids using silicon microchips. PON
2018 Rapid multiplex nucleic acid amplification test developed using paper chromatography chip and azobenzene-modified oligonucleotides. KDCC, POC
2018 Rapid Viral Diagnosis of Orthopoxviruses by Electron Microscopy: Optional or a Must? DEM, OPV, PPV
2018 Transfusion Transmissible Infections: Maximizing Donor Surveillance. HIV, TP, TTIs, WHO
10  2018 Zika virus RNA polymerase chain reaction on the utility channel of a commercial nucleic acid testing system. CI, LOD, PCR, UC, ZIKV
11  2017 A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniques. HBV, IU
12  2017 A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios. HBV, ID, MP6, OBI, PI, VL
13  2017 Changing landscape of hepatitis C virus-positive donors. HCV
14  2017 Excluding Anti-cytomegalovirus Immunoglobulin M-Positive Cord Blood Units Has a Minimal Impact on the Korean Public Cord Blood Bank Inventory. CBUs, CMV
15  2017 Nucleic Acid Amplification Test For Detection Of West Nile Virus Infection In Pakistani Blood Donors. ID-NAT, RPB, WNV
16  2017 Nucleic acid amplification testing in Indian blood banks: A review with perspectives. HepB, ID-NAT
17  2017 Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB. CI, MTC, RIF, TB
18  2017 Relative analytical sensitivity of donor nucleic acid amplification technology screening and diagnostic real-time polymerase chain reaction assays for detection of Zika virus RNA. ZIKV
19  2017 Use of supplemental anti-HBc testing of donors showing non-discriminating reactive results in multiplex nucleic acid testing. NDR
20  2017 Validation of a PCR coupled to a microarray method for detection of mycoplasma in vaccines. LOD, PCR
21  2017 [THE IMPLEMENTATION OF NAT-SCREENING OF INFECTIONS IN BLOOD DONORS OF THE REPUBLIC OF KAZAKHSTAN]. ---
22  2016 A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques. EBV, IU
23  2016 A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. HCMV, IU
24  2016 Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Partyof the German Society for haematology and Medical Oncology. CRVs
25  2016 Comparing Luminex NxTAG-Respiratory Pathogen Panel and RespiFinder-22 for multiplex detection of respiratory pathogens. NxTAG-RPP, RF-22, RTI
26  2016 Duration of Dengue Viremia in Blood Donors and Relationships Between Donor Viremia, Infection Incidence and Clinical Case Reports During a Large Epidemic. CI, Ig, TMA
27  2016 Genome Sequence of a Candidate World Health Organization Reference Strain of Zika Virus for Nucleic Acid Testing. WHO, ZIKV
28  2016 Multicenter Evaluation of Whole-Blood Epstein-Barr Viral Load Standardization Using the WHO International Standard. EBV, EDL, SD
29  2016 Study on Evaluation of Alanine Aminotransferase (ALT) as Surrogate Marker in Hepatitis Virus Test. ALT, BMI, gamma-GTP
30  2015 Automated nucleic acid amplification testing in blood banks: An additional layer of blood safety. ELISA, HBV, HCV, HIV, TTIs
31  2015 Collaborative study for the characterization of a chikungunya virus RNA reference reagent for use in nucleic acid testing. CHIKV, CHIKV-RR, FDA
32  2015 Development of Lentivirus-Based Reference Materials for Ebola Virus Nucleic Acid Amplification Technology-Based Assays. ---
33  2015 Diagnostic performance of near-patient testing for influenza. DAD, TAT
34  2015 Evaluation of the Bio-Rad Geenius HIV 1/2 Confirmation Assay as an Alternative to Western Blot in the Korean Population: A Multi-Center Study. WB
35  2015 Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan. anti-HCV, HBV
36  2015 Standardization of NAT for Blood-Borne Pathogens. ECBS, WHO ISs
37  2015 What is the meaning of a nonresolved viral nucleic acid test-reactive minipool? anti-HBc, Ct, HBsAg, HBV, ID, MP
38  2015 World Health Organization International Standard To Harmonize Assays for Detection of Mycoplasma DNA. ECBS, WHO
39  2015 [Epidemiologic Survey of Blood Donors with HBsAg⁻/HBV DNA⁺ in Chinese Xiamen Area]. ---
40  2014 A pilot study on screening blood donors with individual-donation nucleic acid testing in China. EIA, HBV, HCV, HIV-1, ID
41  2014 Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays. NIBSC
42  2014 Changes in the prevalence, incidence and residual risk for HIV and hepatitis C virus in Southern Brazilian blood donors since the implementation of NAT screening. HCV, HIV
43  2014 Current testing strategies for hepatitis C virus infection in blood donors and the way forward. EIAs, HCV
44  2014 Detection and identification of occult HBV in blood donors in Taiwan using a commercial, multiplex, multi-dye nucleic acid amplification technology screening test. ---
45  2014 Gastrointestinal pathogens detected by multiplex nucleic acid amplification testing in stools of pediatric patients and patients returning from the tropics. DAD
46  2014 Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. anti-HCV, HCC, HCV
47  2014 Improving the safety of blood transfusion by using a combination of two screening assays for hepatitis C virus. EIAs, HCV
48  2014 Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors. ---
49  2014 Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany. CE
50  2014 [Sensitivity of the COBAS AmpliScreen™ HIV-1 test v1.5 for HIV-1 detection]. ---
51  2013 A 10-year human hepatitis B virus nucleic test external quality assessment in China: continual improvement. EQA, HBV
52  2013 A collaborative study to establish the first National Standard for HIV-1 RNA nucleic acid amplification techniques (NAT) in Taiwan. HIV-1, IS, IU, WHO
53  2013 Blood screening for human immunodeficiency virus: a new algorithm to reduce the false-positive results. ELISA, HIV, PPVs, WB
54  2013 Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. CMV
55  2013 Costs and outcomes of laboratory diagnostic algorithms for the detection of HIV. IA
56  2013 Degenerate polymerase chain reaction strategy with DNA microarray for detection of multiple and various subtypes of virus during blood screening. HBV, HCV, HIV, PVB19, WNV
57  2013 Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture. HAV
58  2013 Hepatitis C virus and nonliver solid organ transplantation. HCV
59  2013 How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing. HIV-1, LTR
60  2013 Performance of the new HIV-1/2 diagnostic algorithm in Florida's public health testing population: a review of the first five months of utilization. AHI, EHI, IA, MS, TAT
61  2013 Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis. Ab, HCV, HIV, HIV, QALY, SOT
62  2013 Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. HBV, ID-NAT, JRC, OBI, TT-HBV, WP
63  2013 Routine screening of blood donations at Qingdao central blood bank, China, for hepatitis B virus (HBV) DNA with a real-time, multiplex nucleic acid test for HBV, hepatitis C virus, and human immunodeficiency virus Types 1 and 2. HBe, HBsAg, HBV
64  2013 [Immunoreaction and blood transfusion--chairmen's introductory remarks]. TACO, TRALI
65  2012 Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. HIV-1
66  2012 Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays. M1-M4, NIBSC, WHO
67  2012 Cost-effectiveness of additional blood screening tests in the Netherlands. CEAs, HAV, HBV, HCV, HIV, ICER, QALY
68  2012 Current practices and evaluation of screening solid organ donors for West Nile virus. OPOs, SOT, WNV
69  2012 Novel approach for detection of hepatitis E virus infection in German blood donors. HEV
70  2012 Nucleic Acid Amplification Based Diagnostic of Lyme (Neuro-)borreliosis - Lost in the Jungle of Methods, Targets, and Assays? PCR
71  2012 Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti-HBc titres or high anti-HBc titres with high anti-HBs titres in Japan: a prospective, individual NAT study of transfusion-transmitted HBV, HCV and HIV infections. JRC
72  2012 The detection of occult HBV infection in patients with HBsAg negative pattern by real-time PCR method. HBV, RT
73  2012 The distribution of hepatitis B virus genotypes in Thailand. HBsAg, HBV
74  2011 Genomic detection of human immunodeficiency virus (HIV) by nucleic acid amplification test in a frequent platelet donor during the pre-seroconversion period. HIV
75  2011 Hepatitis B and hepatitis C virus in Thai blood donors. EPI, HBV, HCV, TTI
76  2011 Interlaboratory study to evaluate the performance of laboratories involved in West Nile virus RNA screening of blood and blood components by nucleic acid amplification testing in Italy. WNV
77  2011 Magnetic bead technology for viral RNA extraction from serum in blood bank screening. HIV, RT-PCR
78  2011 Mycoplasma testing of cell substrates and biologics: Review of alternative non-microbiological techniques. ---
79  2011 Point-of-care testing system enabling 30 min detection of influenza genes. POCT, RT-PCR
80  2011 Preanalytical stability of HIV-1 and HCV RNA: impact of storage and plasma separation from cells on blood donation testing by NAT. HCV, HIV-1, PEI
81  2011 Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. HEV, RT-PCR
82  2011 Suitability of an automated nucleic acid extractor (easyMAG) for use with hepatitis C virus and human immunodeficiency virus type 1 nucleic acid amplification testing. HBV, HCV, HIV, LODs
83  2011 The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Ig, PCR
84  2011 West Nile virus: the Italian national transplant network reaction to an alert in the north-eastern region, Italy 2011. WNV
85  2011 World Health Organization collaborative study to calibrate the 3rd International Standard for Hepatitis C virus RNA nucleic acid amplification technology (NAT)-based assays. HCV, IUs
86  2011 [Identification of enteroviruses from central nervous system infections by RT-PCR and cell culture methods]. CNS, CSF, RT-PCR
87  2011 [Simultaneous multiple assay (Luminex xTAG respiratory viral panel FAST assay) efficacy in human respiratory virus detection]. CoV, Inf.V, RVP FAST
88  2010 Are isolated anti-HBc blood donors in high risk group? The detection of HBV DNA in isolated anti-HBc cases with nucleic acid amplification test (NAT) based on transcription-mediated amplification (TMA) and HBV discrimination. HBV, TMA
89  2010 Can the nucleic acid amplification test (NAT) be an alternative to the serologic tests? A prospective study, the results of 18,200 blood donors from the Turkish Red Crescent. TMA
90  2010 Collaborative study to establish a replacement World Health Organization International Standard for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays. IU
91  2010 Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA. ECBS, SG
92  2010 External quality assessment programmes for detection of HCV RNA, HIV RNA and HBV DNA in plasma: improved proficiency of the participants observed over a 2-year period. EQAPs, HBV, HCV, HIV
93  2010 Health economics of blood transfusion safety--focus on sub-Saharan Africa. ---
94  2010 Quarantine Plasma: Quo vadis? FFP
95  2010 The implementation of nucleic acid amplification technology testing for living tissue donors. ---
96  2010 Tissue donation and virus safety: more nucleic acid amplification testing is needed. HBc, HBsAg, HBV, HCV, HIV
97  2010 Update of pathogen reduction technology for therapeutic plasma. WNV
98  2010 Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7. LOD
99  2010 [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus]. HAV, PPV
100  2010 [Viral safety of biologicals: evaluation of hepatitis C virus (HCV) nucleic acid amplification test (NAT) assay and development of concentration method of HCV for sensitive detection by NAT]. HCV, PEI